TheChek News Flow

http://www.globes.co.il/en/article-tevas-desheh-copaxone-has-a-long-life-ahead-of-it-1001034852

As for the proposed deal to buy Mylan, Desheh said, "Teva is a very focused company. It continually improves. We are focused on that even while we deal with the next matter (buying Mylan). Huge quantities of words have poured forth in the international and Israeli press and media. I shan't say anything new on the subject. Teva told Mylan that it was interested in buying it. It was done in a correct, orderly and respectful way, and received the response you have all seen. This response received a respectful and orderly response from us that talked about substance. We believe that the deal will create consolidation in the generics industry, that it's the right deal, for Teva, Mylan and the shareholders. It's that rare kind of deal that can generate value for the shareholders of both companies. "For anyone who doesn't remember, we work for our shareholders, and not the other way around. Creating value for the shareholders is one of the main goals. There are other goals: the workers are important, as are the customers, but the people who pay our salaries are the shareholders. Analysts who have looked and analyzed, people who cover the industry, say that this is a deal that can generate significant value, at a low level of risk."